Citius Pharmaceuticals Secures Funding for LYMPHIR™ Launch in Oncology Market

Citius Oncology Strengthens Financial Position for LYMPHIR™ Launch

Citius Oncology, Inc., a subsidiary of Citius Pharmaceuticals, Inc., announces a significant strategic initiative aimed at bolstering its financial capabilities to support the upcoming commercial launch of its innovative cancer immunotherapy, LYMPHIR™. This therapy specifically targets cutaneous T-cell lymphoma (CTCL), a challenging condition for patients. In a recent move, the company enters into a definitive agreement with a healthcare-focused investor to sell over 1.28 million shares of its common stock at $1.09 per share. This transaction not only strengthens their cash reserves but also underscores the confidence of investors in Citius’ potential to deliver groundbreaking treatments in oncology.

Alongside the registered direct offering, Citius Oncology secures a private placement involving more than 15 million shares and corresponding warrants, further consolidating its financial position. The total gross proceeds from these offerings are expected to reach around $18 million, which will be pivotal for the commercial rollout of LYMPHIR™ and essential for general corporate purposes. The company’s partnership with H.C. Wainwright & Co. as the exclusive placement agent highlights the strategic intent behind these financial maneuvers, ensuring that they are well-positioned to meet the operational demands of launching a novel cancer treatment.

The fundraising efforts reflect Citius Oncology’s commitment to advancing its product pipeline while enhancing its capabilities within the oncology sector. With the anticipated funds, the company can focus on marketing strategies, regulatory compliance, and other critical areas necessary for a successful product launch. As the company prepares for the closing of these transactions, which is anticipated shortly, it reinforces its dedication to providing innovative solutions for patients suffering from CTCL and other malignancies.

In addition to the financial maneuvers, this strategic initiative comes at a crucial time for Citius Oncology as it seeks to establish itself in a competitive market. The launch of LYMPHIR™ represents not just a potential revenue stream, but also a significant advancement in treatment options for patients facing CTCL. As the company navigates this critical phase, it remains focused on leveraging its resources effectively to enhance patient outcomes.

Ultimately, Citius Oncology's proactive approach in securing funding signifies its readiness to tackle the challenges of the oncology market. By prioritizing the successful launch of LYMPHIR™ and reinforcing its operational foundation, the company aims to make a meaningful impact in the lives of patients battling cancer.